A multidisciplinary pulmonary rehabilitation program has become an important part of the treatment of chronic obstructive pulmonary disease. It can improve both exercise tolerance and health related quality of life in these patients. Exercise training has to be included for the program to be successful.

The intensity of the training is of great importance: there is more physiological benefit in high-intensity training, compared to moderate-intensity training. High-intensity training results in reduced levels of blood lactate and pulmonary ventilation at a given heavy work rate. High-intensity training is limited in COPD patients because of exercise-induced dyspnoea. Flow limitation, as a consequence of increased ventilatory demands of exercise, causes a breathing pattern with greater demands on their inspiratory muscles: this results in a pattern of low tidal volume and high-frequency breathing. Increased inspiratory muscle work causes dyspnoea and limitation in exercise intensity. Artificial ventilatory assistance could improve exercise tolerance and hence help severe COPD patients to achieve a higher level of training. It could help to unload and assist the overburdened ventilatory muscles and give a possibility for higher levels of exercise intensity.

In this review article we will discuss the effectiveness and feasibility of training with ventilatory aids.

Transcutaneous carbon dioxide (PtCO(2)) monitoring offers a potentially non-invasive and continuous means to determine the arterial carbon dioxide tension (PaCO(2)). ED studies of agreement between PtCO(2) and PaCO(2) have had conflicting findings and have not been targeted to subgroups with severe ventilatory disturbance such as those requiring non-invasive ventilation [NIV]. Our aim is to determine agreement between PtCO(2) and PaCO(2) for patients undergoing NIV for respiratory failure.

METHODS: This prospective observational study included a convenience sample of patients undergoing NIV for respiratory failure who required arterial blood gas analysis as part of their care. Data collected included patient demographics, indication for NIV, diagnosis, vital signs, and pH, PaCO(2) and PtCO(2). The outcome of interest was agreement between PaCO(2) and PtCO(2). Analysis was made using descriptive statistics, Bland-Altman techniques, Mann-Whitney U test and Fisher/Chi square tests.

RESULTS: 46 comparisons were analysed. Median age was 69 [IQR 65-79], 67% male; median PaCO(2) 60 mmHg [IQR 46-70] and median pH 7.35 [IQR 7.30-7.38]. Average difference between PaCO(2) and PtCO(2) was 6.1 mmHg with 95% limits of agreement -10.1-22.3 mmHg. Thirty seven comparisons [80%] were within 10 mmHg [95% CI 66-90%]. Difference >10 mmHg was associated with increasing PaCO(2) [p = 0.001; median difference 19.6 mmHg, 95% CI 9.2-30.4 mmHg]. All cases with difference >10 mmHg had PaCO(2) > 60 mmHg.

CONCLUSION: In patients undergoing NIV, agreement between PaCO(2) and PtCO(2) was sub-optimal, with unacceptably wide 95% limits of agreement. PtCO(2) cannot be recommended as a substitute for PaCO(2) testing in this group.

Noninvasive pressure support ventilation (NIPSV) and continuous positive airway pressure (CPAP) are both advocated in the treatment of cardiogenic pulmonary edema (CPE); however, the superiority of one technique over the other has not been clearly demonstrated. With regard to its physiological effects, we hypothesized that NIPSV would be better than CPAP in terms of clinical benefit.

METHODS: In a prospective, randomized, controlled study performed in four emergency departments, 200 patients were assigned to CPAP (n = 101) or NIPSV (n = 99). Primary outcome was combined events of hospital death and tracheal intubation. Secondary outcomes included resolution time, myocardial infarction rate, and length of hospital stay. Separate analysis was performed in patients with hypercapnia and those with high B-type natriuretic peptide (>500 pg/ml).

RESULTS: Hospital death occurred in 5 (5.0%) patients receiving NIPSV and 3 (2.9%) patients receiving CPAP (p = 0.56). The need for intubation was observed in 6 (6%) patients in the NIPSV group and 4 (3.9%) patients in the CPAP group (p = 0.46). Combined events were similar in both groups. NIPSV was associated to a shorter resolution time compared to CPAP (159 ± 54 vs. 210 ± 73 min; p < 0.01), whereas the incidence of new myocardial infarction was not different between both groups. Similar results were found in hypercapnic patients and those with high B-type natriuretic peptide.

CONCLUSIONS: During CPE, NIPSV accelerates the improvement of respiratory failure compared to CPAP but does not affect primary clinical outcome either in overall population or in subgroups of patients with hypercapnia or those with high B-type natriuretic peptide.

Mesenchymal stem cells (MSCs) are multipotent adult stem cells present in all tissues, as part of the perivascular population. As multipotent cells, MSCs can differentiate into different tissues originating from mesoderm ranging from bone and cartilage, to cardiac muscle.

MSCs are an excellent candidate for cell therapy because they are easily accessible, their isolation is straightforward, they can be bio-preserved with minimal loss of potency, and they have shown no adverse reactions to allogeneic versus autologous MSCs transplants. Therefore, MSCs are being explored to regenerate damaged tissue and treat inflammation, resulting from cardiovascular disease and myo-cardial infarction (MI), brain and spinal cord injury, stroke, diabetes, cartilage and bone injury, Crohn's disease and graft versus host disease (GvHD).

Most of the application and clinical trials involve MSCs from bone marrow (BMMSCs). Transplantation of MSCs from bone marrow is considered safe and has been widely tested in clinical trials of cardiovascular, neurological, and immunological disease with encouraging results. There are examples of MSCs utilization in the repair of kidney, muscle and lung. The cells were also found to promote angiogenesis, and were used in chronic skin wound treatment. Recent studies involve also mesenchymal stem cell transplant from umbilical cord (UCMSCt). One of these demonstrate that UCMSCt may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus (SLE), and therefore this source of MSCs need deeper studies and require more attention.

However, also if there are 79 registered clinical trial sites for evaluating MSC therapy throughout the world, it is still a long way to go before using these cells as a routinely applied therapy in clinics.